$15.31
2.36%
Nasdaq, Jan 02, 10:04 pm CET
ISIN
US61225M1027
Symbol
GLUE

Monte Rosa Therapeutics Inc Stock price

$15.31
-0.10 0.65% 1M
+10.58 223.68% 6M
-0.37 2.36% YTD
+8.20 115.33% 1Y
+7.70 101.18% 3Y
-5.87 27.71% 5Y
-5.87 27.71% 10Y
-5.87 27.71% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.37 2.36%
ISIN
US61225M1027
Symbol
GLUE
Industry

Key metrics

Basic
Market capitalization
$997.0m
Enterprise Value
$605.7m
Net debt
positive
Cash
$391.3m
Shares outstanding
61.8m
Valuation (TTM | estimate)
P/E
61.2 | negative
P/S
5.5 | 7.2
EV/Sales
3.3 | 4.4
EV/FCF
4.2
P/B
4.1
Financial Health
Equity Ratio
50.8%
Return on Equity
-32.6%
ROCE
2.1%
ROIC
27.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$181.5m | $139.2m
EBITDA
$16.8m | $-41.8m
EBIT
$8.5m | $-34.6m
Net Income
$21.0m | $-17.5m
Free Cash Flow
$145.0m
Growth (TTM | estimate)
Revenue
1,111.9% | 84.0%
EBITDA
113.9% | 42.7%
EBIT
106.6% | 57.4%
Net Income
117.5% | 76.0%
Free Cash Flow
331.0%
Margin (TTM | estimate)
Gross
-
EBITDA
9.3% | -30.1%
EBIT
4.7%
Net
11.5% | -12.6%
Free Cash Flow
79.9%
More
EPS
$0.3
FCF per Share
$2.3
Short interest
14.0%
Employees
142
Rev per Employee
$530.0k
Show more

Is Monte Rosa Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Monte Rosa Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

Buy
87%
Hold
13%

Financial data from Monte Rosa Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
182 182
1,112% 1,112%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 35 35
2% 2%
19%
- Research and Development Expense 138 138
26% 26%
76%
17 17
114% 114%
9%
- Depreciation and Amortization 8.33 8.33
5% 5%
5%
EBIT (Operating Income) EBIT 8.51 8.51
107% 107%
5%
Net Profit 21 21
118% 118%
12%

In millions USD.

Don't miss a Thing! We will send you all news about Monte Rosa Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Monte Rosa Therapeutics Inc Stock News

Positive
Investors Business Daily
20 days ago
Monte Rosa Therapeutics surged Tuesday after the biotech said every patients in a prostate cancer study responded to its treatment.
Neutral
GlobeNewsWire
20 days ago
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, including 2 patients with RECIST responses and 2 with stable disease  Combination of MRT-2359 and enzalutamide was generally well-tolerated with primarily Grade 1-2 adverse events Company plans to ini...
Neutral
GlobeNewsWire
21 days ago
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Tuesday, December 16, 2025, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing...
More Monte Rosa Therapeutics Inc News

Company Profile

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Head office United States
CEO Markus Warmuth
Employees 142
Founded 2019
Website www.monterosatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today